Michael R. Bennett, PhD
Director, Biomarker Laboratory
research interests include developing early diagnostic markers for pediatric diseases, such as acute kidney injury, nephrotic syndrome and lupus nephritis. Dr. Bennett is also interested in unraveling the etiology of focal segmental glomerulosclerosis by studying both the underlying genetic and proteomic patterns associated with the disease.
513-636-8349
michael.bennett@cchmc.org
Michael R. Bennett, PhD
Director, Biomarker Laboratory
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Diagnostic markers for pediatric diseases; acute kidney injury; nephrotic syndrome, lupus nephritis; focal segmental glomerulosclerosis; mechanisms of neurologic disease
Biography
Education and Training
Research Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH
PhD: University of Cincinnati College of Medicine, Cincinnati, OH, 2004.
BA: Thomas More College, Crestview Hills, KY, 1997.
Publications
View PubMed Publications
Krawczeski C, Vandevoorde R, Kathman T, Bennett M, Woo J, Wang Y, Griffiths R, Devarajan P. Serum Cystatin C Is an Early Predictive Biomarker of Acute Kidney Injury after Pediatric Cardiopulmonary Bypass. CJASN. 2010; 2010 Sep;5(9):1552-7.
Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, D'amico G, Goldsmith D, Devarajan P, Bellomo R. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 2009;36(3):381-4
Stella CL, Bennett MR, Devarajan P, Greis K, Wyder M, Macha S, Rao M, Jodicke C, Moussa H, How HY, Myatt L, Webster R, Sibai BM.Preterm labor biomarker discovery in serum using 3 proteomic profiling methodologies.Am J Obstet Gynecol. 2009;201(4):387.e1-13.
Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Möckel M, Matalanis G, Dragun D, Haase-Fielitz A. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009;88(1):124-30
Haase-Fielitz A, Bellomo R, Devarajan P, Bennett M, Story D, Matalanis G, Frei U, Dragun D, Haase M. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant. 2009;24:3349-3354.
Bennett M, Ravipati N, Ross G, Nguyen M, Hirsch R, Beekman R, Rovner L, Devarajan P. Using proteomics to identify pre-procedural risk factors for contrast induced nephropathy. Proteomics – Clinical Applications. 2008;2(7-8):1058-1064.
Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, Kasza KE, O'Connor MF, Konczal DJ, Trevino S, Devarajan P, Murray PT. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008;74(8):1059-1069.
Lavery AP, Meinzen-Derr JK, Anderson E, Ma Q, Bennett MR, Devarajan P, Schibler KR. Urinary NGAL in premature infants. Pediatr Res. 2008;64(4):423-8.
Bennett M, Dent C, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J, Devarajan P. Urine NGAL predicts acute kidney injury, morbidity and mortality after cardiac surgery: a prospective study. Clinical Journal of the American Society of Nephrology. 2008;3(3): 665-673.
Bennett M, Czech K, Arend L, Witte D, Devarajan P, Potter, S. Analysis of the glomerular gene expression profile in patients with focal segmental glomerulosclerosis. Experimental Nephron. 2007;107(1): e30-40
Suzuki M, Ross GF, Wiers K, Nelson S, Bennett MR, Passo MH, Devarajan P, Brunner HI. Identification of a urinary proteomic signature for lupus nephritis. Pediatric Nephrology. 2007;22(12): 2047-2057.
Grants
|
John J. Bissler, MD
Associate Program Director for Research and Academic Careers
focuses on proliferative renal diseases such as tuberous sclerosis complex, the polycystic kidney diseases, renal tumors, von Hippel-Lindau disease, and Birt–Hogg–Dubé syndrome. The research includes mechanisms of mutation, and the cell biology of disease. Dr. Bissler extends his bench research into clinical trials in order to find new and better treatments for his patients. Visit the Bissler Lab.
513-636-1201
john.bissler@cchmc.org
John J. Bissler, MD
Associate Program Director for Research and Academic Careers
Clark D. West Chair of Nephrology
Director, Nephrology Fellowship Training Program
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsProliferative renal diseases; renal cystic disease; solid lesions Research InterestsProliferative renal diseases; polycystic kidney disease; tuberous sclerosis complex; Von Hippel-Lindau disease; Birt-Hogg-Dube syndrome and renal cancers; understanding the mechanisms of mutation leading to these diseases as well as the consequences of mutations in hope of finding effected treatments Visit the Bissler Lab.
Biography
Education and Training
MD: Northeastern Ohio University College of Medicine, Rootstown, OH, 1985 Residency: Pediatrics, Children's Medical Center, Akron, OH Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH Certification: Pediatrics, 1989; Pediatric Nephrology, 1992
Publications
View PubMed Publications
Dixon BP, Hulbert JC, and Bissler JJ. Tuberous Sclerosis Complex Renal Disease. Nephron. 2011;118(1):e15-20. Siroky BJ, Yin H, Bissler JJ. Molecular Insights into Tuberous Sclerosis Complex Renal Disease. Pediatric Nephrol. 2010 Dec 9. Mrug M, and Bissler JJ. Simulation of real-time ultrasound-guided renal biopsy. Kidney Int. 2010 Oct;78(7):705-7. Bissler JJ, Siroky BJ, Yin H. Glomerulocystic kidney disease. Pediatric Nephrol. 2010 Oct;25(10):2049-56; quiz 2056-9. Liu G, Bissler JJ, Sinden RR, Leffak M. Replication dependent instability at (CTG)•(CAG) repeat hairpins in human cells. Nat Chem Biol. 2010 Sep;6(9):652-9.
Johnson SR, and the Review Panel of the European Respiratory Society Lymphangio-leiomyomatosis Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35:14-26.
Siroky BJ, Czyzyk-Krzeska MF, Bissler JJ. Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? Nat Clin Pract Nephrol. 2009;5(3):143-56.
Schmithorst VJ, Altes TA, Young LR, Franz DN, Bissler JJ, McCormack FX, et al. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis . Am J Roentgenol. 2009;192(4):1037-44.
Dixon BP, Chu A, Henry J, Kim R, Bissler JJ. Increased cancer risk of augmentation cystoplasty: Possible role for hyperosmolal microenvironment on DNA damage recognition . Mutat Res. 2009; 670:88-95. Book ChaptersBissler JJ, Henske E. Tuberous Sclerosis Complex: From Genes to Therapeutics. Chapter 15. Renal Manifestations of Tuberous Sclerosis Complex. In: Whittemore V, Henske EP, Kwiatkowski D, editors. New York: Elisivier; 2009.
Grants
Placebo-Controlled Randomized Multicenter mTOR Inhibitor Trial for Angiomyolipomata. Principal Investigator. Jun 2006 – Jun 2014.
|
Bradley P. Dixon, MD
focuses on the recognition and repair of DNA damage within the urinary microenvironment, specifically as it relates to the increased risk of malignancy in the augmented bladder. Dr. Dixon also has clinical and translational research interests in complement-mediated diseases such as atypical hemolytic uremic syndrome, as well as cystic kidney diseases such as tuberous sclerosis and polycystic kidney disease.
513-636-4531
bradley.dixon@cchmc.org
Bradley P. Dixon, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
DNA damage response; DNA repair; biology of bladder augmentation; atypical hemolytic uremic syndrome
Biography
Bradley Dixon, MD, joined the faculty in the Division of Nephrology and Hypertension at Cincinnati Children's in 2006. He has received support for his research from a William Cooper Procter Pediatric Research Award in 2006, a Child Health Research Career Development Award (K12) in 2009, and is currently funded by a K08 through the National Institute of Diabetes, Digestive and Kidney Diseases. Dr. Dixon’s research interests focus on the effects of hyperosmolal microenvironments such as the renal medulla and urinary bladder upon vital cellular processes such as the DNA damage response pathway and activation of cell cycle checkpoints and apoptosis. This research focus attempts to understand the susceptibility of the gastrointestinal tissues used in bladder reconstructions to carcinogenesis.
In addition to his basic science research interests, Dr. Dixon has a clinical research interest in thrombotic microangiopathies such as atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), and is an investigator in a number of clinical trials and registries for these diseases. Dr. Dixon is also involved in clinical research studying cystic kidney diseases such as tuberous sclerosis complex (TSC) and autosomal dominant polycystic kidney disease (ADPKD).
Dr. Dixon is the assistant program director for the Pediatric Nephrology Fellowship Training Program, serves in an advisory capacity to the Adaptive Care Team, and on the Board of the Cincinnati Pediatric Society, most recently as president in 2011.
Education and Training
BA: College of Wooster, Wooster, OH, 1995.
MD: University of Tennessee, Memphis, 1999.
Residency: Cincinnati Children's Hospital Medical Center, 1999-2002.
Chief Residency: Cincinnati Childrens Hospital, 2002-2003.
Fellowship: Cincinnati Childrens Hospital, 2003-2006.
Publications
View PubMed Publications
Dixon BP, Henry J, Siroky BJ, Chu A, Groen PA, Bissler JJ. Cell Cycle Control and DNA Damage Response of Conditionally Immortalized Urothelial Cells. PLoS ONE. 2011 Jan 28;6(1):e16595. Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15-20.
Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010 Mar;10(3):687-91.
Dixon BP, Chu A, Henry J, Kim R, Bissler JJ. Increased cancer risk of augmentation cystoplasty: possible role for hyperosmolal microenvironment on DNA damage recognition. Mutat Res. 2009 Nov 2;670(1-2):88-95.
Dixon BP, Lu L, Chu A, Bissler JJ. RecQ and RecG helicases have distinct roles in maintaining the stability of polypurine.polypyrimidine sequences. Mutat Res. 2008 Aug 25;643(1-2):20-8. Dixon BP, McEnery P, Goebel J. Immunobiology of paediatric renal transplantation. Progress in Paediatric Urology. 2008;10:165-182.
Bissler JJ, Dixon BP. A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol. 2005 May;20(5):558-66.
Dixon BP, Devarajan P, Mitsnefes M. Neonatal renovascular hypertension due to prenatal traumatic retroperitoneal hematoma. Pediatr Nephrol. 2005 May;20(5):670-2.
Grants
DNA Damage and Response in the Bladder Microenvironment. Principal Investigator. National Institutes of Health. Jul 2011 - Apr 2015. #K08 DK081737.
|
Jens W. Goebel, MD
Clinical Director, Nephrology and Hypertension
is involved in multi-center projects investigating non-invasive predictors of kidney transplant outcome and the influence of immunosuppressive regimens on transplantation tolerance. He is also conducting collaborative studies of the pharmacokinetics, genetics and dynamics of drugs used for anti-rejection prophylaxis, and participating in efforts to better understand our patients’ adherence to their immunosuppressive regimen.
513-636-4531
jens.goebel@cchmc.org
Jens W. Goebel, MD
Clinical Director, Nephrology and Hypertension
Medical Director, Kidney Transplantation
Clinical Director, Kidney Transplantation
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsOrgan transplantation in children Research InterestsTransplant-relevant immunology
Biography
Dr. Goebel was recruited by Cincinnati Children's Hospital Medical Center in 2002 from the University of Kentucky to enhance the institution's kidney transplant program. His efforts along these lines focus both on further improving the clinical care of pediatric kidney transplant recipients and their families, as well as advancing basic and translational investigations into immunological aspects especially relevant to the field of transplantation.
Education and Training
MD: University of Heidelberg (Germany), 1991.
Residency and Chief Residency: Department of Pediatrics, University of South Alabama, Mobile, AL, 1991 to 1995.
Fellowship: Section of Pediatric Nephrology, Tulane University Medical Center, New Orleans, LA, 1995 to 1998
Certifications: General Pediatrics, 1994, 2002; Pediatric Nephrology, 1999.
Publications
View PubMed Publications
Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7.
Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95.
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24.
Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, Martz K, Bucuvalas J; SPLIT Renal Function Working Group. Glomerular filtration rate following pediatric liver transplantation--the SPLIT experience. Am J Transplant. 2010 Dec;10(12):2673-82.
Pai AL, Gray E, Kurivial K, Ross J, Schoborg D, Goebel J. The Allocation of Treatment Responsibility scale: a novel tool for assessing patient and caregiver management of pediatric medical treatment regimens. Pediatr Transplant. 2010 Dec;14(8):993-9.
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Pai AL, Ingerski LM, Perazzo L, Ramey C, Bonner M, Goebel J. Preparing for transition? The allocation of oral medication regimen tasks in adolescents with renal transplants. Pediatr Transplant. 2011 Feb;15(1):9-16.
Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9. Herzer M, Goebel J, Cortina S. Transitioning cognitively impaired young patients with special health needs to adult-oriented care: collaboration between medical providers and pediatric psychologists. Curr Opin Pediatr. 2010 Oct;22(5):668-72. Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23.
Grants
Center-PI / Co-Investigator / Collaborator: NIH UO1 grant: Noninvasive Monitoring to Predict Outcome in de novo Kidney Transplant Recipients (CTOT-01, Protocol Chair: P. Heeger, MD, City), commenced in late 2005 and ongoing NIH UO1 grant: Health and Literacy in Child and Adult Assessment: Expanded Testing of the Pediatric PROMIS (Patient Reported Outcomes Measurement Information System) Tool (Sponsor: D. DeWalt, MD, MPH, ), ongoing NIH UO1 grant: Chronic Kidney Disease in Children (CKID, PI: B. Warady, MD, Children’s Mercy Hospital, Kansas City, MO), ongoing NIH RO1 grant: Calcineurin Inhibitor Minimization And Foxp3+ Tregs Post-Transplant (PIs: Wayne Hancock, MD, Children’s , and John Bucuvalas, MD, Cincinnati Children’s Hospital), ongoing Midwest Pediatric Nephrology Consortium: Assessing and Implementing Transition to Adult Care in Children with CKD (PI: M. Ferris, MD, MPH, PhD, ), ongoing Amgen Pharmaceuticals: Pediatric Anemia Correction Study (Protocol 20050256), ongoing Roche Pharmaceuticals: Development of Population Pharmacokinetic models of Mycophenolic Acid for use in Bayesian Dose Individualization in Pediatric Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing Cincinnati Children’s Hospital Medical Center Outcomes Research Award: Validation of a Real-Time Adherence Assessment System (PI: A. Pai, PhD, Cincinnati Children’s Hospital), ongoing Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Pharmacogenetics of Mycophenolic Acid in Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Biomarkers for Patient-tailored Therapies in Pediatric Lupus Nephritis using Mycophenolic Acid (PI: H. Brunner, Cincinnati Children’s Hospital), ongoing Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Pharmacogenetics of IMPDH in Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing
|
Stuart L. Goldstein, MD
Director, Center for Acute Care Nephrology
focuses on all aspects of acute kidney injury (AKI) spanning from translational work in AKI biomarker validation to long-term AKI epidemiology and outcomes. He is specifically interested in improving outcomes in the critically ill child with or at risk for AKI.
513-803-3295
stuart.goldstein@cchmc.org
Stuart L. Goldstein, MD
Director, Center for Acute Care Nephrology
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsAcute kidney injury; continuous renal replacement therapy; end-stage renal disease; health-related quality of life Research InterestsAcute kidney injury epidemiology and biomarkers; health-related quality of life in ESRD; cardiovascular complications and inflammation in ESRD
Biography
Stuart L. Goldstein, MD has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein's main research foci include AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has a strong record of interdisciplinary and inter-institutional collaboration, evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) and its success as well as collaboration with critical care physicians, cardiologists and emergency medicine physicians to study AKI in their populations. This collaboration includes publication of the first article demonstrating the existence of a cardio-renal syndrome in pediatric patients with acute decompensated heart failure. Dr. Goldstein has also performed the only published assessment of novel urinary AKI biomarkers in a heterogeneous group of critically ill children, demonstrating their accuracy to predict AKI development and severity. Dr. Goldstein has been developing a program to investigate and minimize nephrotoxic medication associated AKI in non-critically ill children.
Education and Training
MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.
Residency: Baylor College of Medicine, Houston, TX.
Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.
Publications
View PubMed Publications
Goldstein SL, Devarajan P. Acute kidney injury in childhood: should we be worried about progression to CKD? Pediatr Nephrol. 2011 Apr;26(4):509-22. Du Y, Zappitelli M, Mian A, Bennett M, Ma Q, Devarajan P, Mehta R, Goldstein SL. Urinary biomarkers to detect acute kidney injury in the pediatric emergency center. Pediatr Nephrol. 2011 Feb;26(2):267-74. Moffett BS, Goldstein SL, Adusei M, Kuzin J, Mohan P, Mott AR. Risk factors for postoperative acute kidney injury in pediatric cardiac surgery patients receiving angiotensin-converting enzyme inhibitors. Pediatr Crit Care Med. 2011 Feb 10. Zappitelli M, Moffett BS, Hyder A, Goldstein SL. Acute kidney injury in non-critically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrol Dial Transplant. 2011 Jan;26(1):144-50. Koralkar R, Ambalavanan N, Levitan EB, McGwin G, Goldstein S, Askenazi D. Acute Kidney Injury Reduces Survival in Very Low Birth Weight Infant. Pediatr Res. 2010 Dec 20. Goldstein SL. Continuous renal replacement therapy: mechanism of clearance, fluid removal, indications and outcomes. Curr Opin Pediatr. 2010 Dec 21. Goldstein SL. Urinary kidney injury biomarkers and urine creatinine normalization: a false premise or not? Kidney Int. 2010 Sep;78(5):433-5. Goldstein SL, Chawla L. Renal Angina. Clin J AmSoc Nephrol. 2010 May;5(5):943-9. Sutherland SM, Zappitelli M, Alexander SR, Chua AN, Brophy PD, Bunchman TE, Hackbarth R, Somers MJG, Baum M, Symons JM, Flores FX, Benfield M, Askenazi D, Chand D, Fortenberry JD, Mahan JD, McBryde K, Blowey D, Goldstein SL. Fluid Overload and Mortality in Children Receiving Continuous Renal Replacement Therapy: The Prospective Pediatric Continuous Renal Replacement Therapy Registry. Am J Kidney Dis. 2010 Feb;55(2):316-25.
Grants
PlasmaLyte Gastroenteritis Study. Principal Investigator. Baxter Healthcare. Nov 2010 - Oct 2011. Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis- a comparison of hemodialysis vs. peritoneal dialysis. Principal Investigator. Baxter Healthcare. Dec 2010 - Dec 2011. Optimize Fluid Dosing in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Casey Lee Ball Foundation. Jan 2011 – Dec 2011. Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Casey Lee Ball Foundation. Feb 2011 - Jan 2012. Evaluation of cystatin C and Urine Proteins as Early Biomarkers of AKI in Children Treated with Nephrotoxic Medication. Principal Investigator. The Research Institute of McGill University Health Centre. Jun 2011 – Jun 2012. Center for Acute Care Nephrology Fellowship. Fellowship Director. Funded by Gambra Renal Products. Jan 2011 - Jan 2013. Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis. Principal Investigator. Casey Lee Ball Foundation. Jan 2010 - Dec 2020.
|
David K. Hooper, MD
aims to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of systems capable of delivering that care with high reliability. His primary focus is the prevention of cardiovascular disease through a combination of quality improvement and clinical/translational research methods.
513-803-2114
david.hooper@cchmc.org
David K. Hooper, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Nephrology; kidney transplantation; quality improvement
Biography
David Hooper, MD, MS, holds a joint appointment in the Division of Nephrology and Hypertension and the James M. Anderson Center for Health Systems Excellence. Dr. Hooper aims to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of reliable healthcare systems.
Dr. Hooper's research training includes a master's degree in Clinical and Translational Research from the University of Cincinnati, in addition to advanced training in quality improvement methodology through the Quality Scholars in Transforming Healthcare program at Cincinnati Children’s Hospital. My career focus is to combine clinical outcomes research with quality improvement to reliably prevent cardiovascular disease, the leading cause of long-term death and disability in pediatric transplant recipients.
Education and Training
MD: University of Utah, Salt Lake City, UT 2003.
Residency: Cincinnati Children's Hospital, Cincinnati, OH, 2006.
Chief Residency: Cincinnati Children's Hospital, Cincinnati, OH, 2007.
MS: University of Cincinnati, Cincinnati, OH, 2010.
Fellowship: Cincinnati Children's Hospital, Cincinnati OH, 2010; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, OH, 2008-2011. Certification: Pediatrics, 2006.
Publications
View PubMed Publications
Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95. Kaplan HC, Brady PW, Dritz MC, Hooper DK, Linam WM, Froehle CM, Margolis P. The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q. 2010 Dec;88(4):500-59.
Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg. 2005 Feb;79(2):641-4.
Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer. 2003 Aug 15;98(4):841-53.
Lirazan MB, Hooper D, Corpuz GP, Ramilo CA, Bandyopadhyay P, Cruz LJ, Olivera BM. The spasmodic peptide defines a new conotoxin superfamily. Biochemistry. 2000 Feb 22;39(7):1583-8.
Walker CS, Steel D, Jacobsen RB, Lirazan MB, Cruz LJ, Hooper D, Shetty R, DelaCruz RC, Nielsen JS, Zhou LM, Bandyopadhyay P, Craig AG, Olivera BM. The T-superfamily of conotoxins. J Biol Chem. 1999 Oct 22;274(43):30664-71.
Olivera BM, Walker C, Cartier GE, Hooper D, Santos AD, Schoenfeld R, Shetty R, Watkins M, Bandyopadhyay P, Hillyard DR. Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. Ann N Y Acad Sci. 1999 May 18;870:223-37.
Grants
|
Elizabeth C. Jackson, MD
Director, Healthy Bladder Clinic
has clinical research in types of bedwetting alarms that are useful for nocturnal enuresis, in outcomes of neurogenic bladder, and in the relationship of obesity and kidney stones as well as industry sponsored research in anticholinergics for neurogenic bladder.
513-636-4975
elizabeth.jackson@cchmc.org
Elizabeth C. Jackson, MD
Director, Healthy Bladder Clinic
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Functional bladder disorders; neurogenic bladder; urolithiasis
Biography
Elizabeth C. Jackson, MD, is a pediatric nephrologist recognized in the need for bladder management. Dr. Jackson has recently discontinued her inpatient nephrology role, and is currently focused on outpatient lower urinary tract management. She is the director of the Healthy Bladder Clinic at Cincinnati Children's. The Healthy Bladder Clinic cares for children with functional lower urinary tract disorders. There are more than 1200 visits per year to this clinic.
Education and Training
MD: University of Virginia, Charlottesville, Virginia, 1978.
Residency: Children's Hospital of Pittsburgh, Pittsburgh, PA, 1981.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 1984.
Certification: Pediatrics, 1983; Pediatric Nephrology, 1985.
Publications
View PubMed Publications
Ivancić V, Defoor W, Jackson E, Alam S, Minevich E, Reddy P, Sheldon C. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010 Oct;184(4 Suppl):1768-74. DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul;76(1):242-5. DeFoor W, Clark C, Jackson E, Reddy P, Minevich E, Sheldon C. Risk factors for end stage renal disease in children with posterior urethral valves. J Urol. 2008 Oct;180(4 Suppl):1705-8; discussion 1708. DeFoor W, Minevich E, Jackson E, Reddy P, Clark C, Sheldon C, Asplin J. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008 Jun;179(6):2369-72. DeFoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Erhard M, Minevich E. Urinary metabolic evaluations in normal and stone forming children. J Urol. 2006 Oct;176(4 Pt 2):1793-6. Defoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Minevich E. Results of a prospective trial to compare normal urine supersaturation in children and adults. J Urol. 2005 Oct;174(4 Pt 2):1708-10. Jensen S, Jackson EC, Riley L, Reddy S, Goebel J. Tacrolimus-based immunosuppression with steroid withdrawal in pediatric kidney transplantation -- 4-year experience at a moderate-volume center. Pediatr Transplant. 2003 7:119-124. Strife CF, Prada AL, Clardy CW, Jackson E, Forristal J. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr. 1990 May;116(5):S98-102.
Grants
Comparison of voice and buzzer alarms for nocturnal enuresis. Principal Investigator. Cincinnati Children's Hospital Medical Center. Oct 2011 - present.
|
Paul T. McEnery, MD
has focused his career on the research of membranoproliferative glomerulonephritis and is a key member of the North American Pediatric Renal Transplant Consortium data base. Besides his research in transplantation and immune-mediated renal disease, he also was responsible for bringing the Ronald McDonald House to Cincinnati Children's as well as initiating dialytic therapy for children in Cincinnati.
513-636-4531
paul.mcenery@cchmc.org
Paul T. McEnery, MD
Academic Information
UC Department of Pediatrics
Emeritus Professor of Pediatrics
Show All
Specialties
Glomerulonephritis; vitamin D resistant rickets; care of the child with end-stage renal disease
Biography
Education and Training
MD: Loyola University, Chicago, IL, 1965.
Residency: Children's Hospital Medical Center, Cincinnati, OH.
Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics 1974, 1986, 1993; Pediatric Nephrology, 1974, 1986, 1993.
MBA: Xavier University, 1989.
Publications
View PubMed Publications
DeFoor W, Tackett L, Minevich E, McEnery P, Kitchens D, Reeves D, Sheldon C. Successful renal transplantation in children with posterior urethral valves.J Urol. 2003 Dec;170(6 Pt 1):2402-4. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).J Am Soc Nephrol. 2003 Oct;14(10):2618-22. DeFoor W, Minevich E, McEnery P, Tackett L, Reeves D, Sheldon C. Lower urinary tract reconstruction is safe and effective in children with end stage renal disease.J Urol. 2003 Oct;170(4 Pt 2):1497-500; discussion 1500. Mitsnefes MM, Khoury PR, McEnery PT. Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients.J Pediatr. 2003 Jul;143(1):98-103. Mitsnefes MM, Khoury P, McEnery PT. Body mass index and allograft function in pediatric renal transplantation.Pediatr Nephrol. 2002 Jul;17(7):535-9. Omoloja AA, Racadio JM, McEnery PT. Post-biopsy renal arteriovenous fistula. Pediatr Transplant. 2002 Feb;6(1):82-5. Mitsnefes MM, Omoloja A, McEnery PT. Short-term pediatric renal transplant survival: blood pressure and allograft function.Pediatr Transplant. 2001 Jun;5(3):160-5. Schurman SJ, McEnery PT. Factors influencing short-term and long-term pediatric renal transplant survival.J Pediatr. 1997 Mar;130(3):455-62. McEnery PT. Pediatric renal transplantation: A review of data from north American pediatric renal transplant cooperative study (NAPRTCS).Saudi J Kidney Dis Transpl. 1994 July-September;5(3):336-46. McEnery PT, Alexander SR, Sullivan K, Tejani A. Renal transplantation in children and adolescents: the 1992 annual report of the North American Pediatric Renal Transplant Cooperative Study.Pediatr Nephrol. 1993 Dec;7(6):711-20.
Grants
|
Mark M. Mitsnefes, MD, MS
Pediatric Nephrologist
is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.
513-636-4531
mark.mitsnefes@cchmc.org
Mark M. Mitsnefes, MD, MS
Pediatric Nephrologist
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Nephrology with focus on chronic kidney disease and hypertension
Biography
Mark Mitsnefes, MD, MS, is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease. Dr. Misnefes has received numerous awards, including the Proctor Scolar Award (Cincinnati Children's Research Foundation), the Pediatrician Scientist Award (Children's Health Research Center, NIH), the Clinical Scientist Award (National Kidney Foundation), and has been ranked as one of the Best Doctors in America, 2007-2011.
Education and Training
MD: Gorky Medical Institute, Gorky, Russia, 1985.
Residency: Miami Children's Hospital, Miami, Florida, 1997.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2000. MS: Epidemiology and Biostatistics, University of Cincinnati, Cincinnati, Ohio, 2001. Certifications: Educational Commission for Foreign Medical Graduates (ECFMG), 1995; Pediatrics, 1996; Pediatric Nephrology, 2001, 2008.
Publications
View PubMed Publications
Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD.J Am Soc Nephrol. 2010 Jan;21(1):137-44. Wilson AC, Mitsnefes MM. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis. 2009 Aug;54(2):345-60. Review. Flynn JT, Mitsnefes MM, Pierce C, Cole SR, Parekh RS, Furth SL and Warady BA. Blood pressure in children with chronic kidney disease: Preliminary findings from chronic kidney disease in children cohort study. Hypertension. 2008;52(4):631-7 Weaver DJ Jr, Kimball T, Witt SA, Glascock BJ, Khoury PR, Kartal J, Mitsnefes MM. Subclinical systolic dysfunction in pediatric patients with chronic kidney disease. J Pediatr. 2008 Oct;153(4):565-9. Weaver DJ Jr., Kimball TR, Knilans T, Mays WK, Knecht T, Gerdes YT, Witt S, Glascock BJ, Kartal J, Khoury PR, and Mitsnefes MM. Decreased maximal aerobic capacity in pediatric chronic kidney disease. J Am Soc Nephrol. 2008, 19(3):624-30. Mitsnefes MM, Kimball TR, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Abnormal carotid artery structure and function in children with successful renal transplant. Circulation. 2004; 110:97-101. Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock B, Khoury PR, Daniels SR. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: Role of calcium-phosphorus metabolism. J Am Soc Nephrol. 2005;16:2796-2803. Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR and Daniels SR. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int. 2004;65(4):1461-1466. Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation. 2003;107:864-868 Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Meyer RA, and Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898-902.
Grants
Adiponectin and Cardiovascular Disease in the CKiD Children. Principal Investigator. National Institutes of Health. 2007 - 2011. #R01 DK076957. Modify Dietary Behavior in Adolescents with Elevated Blood Pressure. Co-investigator. National Institutes of Health. 2007 - 2012. Prospective study of chronic kidney disease in children. Co-investigator, Co-chair of the Cardiovascular Committee. National Institutes of Health. 2003 - 2013. #U01 DK-03-012. Cardiovascular disease in children with CKD. Principal Investigator. National Institutes of Health. 2011 - 2016. #K24 DK090070-01.
|
C. Frederic Strife, MD
Emeritus Professor
has focused his research career around immune-mediated renal disease and membranoproliferative glomerulonephritis in particular. Furthermore, Dr. Strife also has been active in understanding how to improve the care of the pediatric dialysis patient.
513-636-4531
fred.strife@cchmc.org
C. Frederic Strife, MD
Emeritus Professor
Director of the Dialysis Unit
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Glomerulonephritis; renal tubular disorders; growth failure in chronic renal disease; dialysis
Biography
Education and Training
MD: College of Medicine and Dentistry of New Jersey, 1968. Residency: Pediatrics, Children's Hospital Medical Center, Cincinnati, OH. Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH. Certification: Pediatrics, 1973; Pediatric Nephrology, 1976.
Publications
View PubMed Publications
Calvo-Garcia MA, Campbell KM, O'Hara SM, Khoury P, Mitsnefes MM, Strife CF. Acquired renal cysts after pediatric liver transplantation: association with cyclosporine and renal dysfunction. Pediatr Transplant. 2008 Sep;12(6):666-71.
Vo NJ, Hammelman BD, Racadio JM, Strife CF, Johnson ND, Racadio JM. Anatomic distribution of renal artery stenosis in children: implications for imaging. Pediatr Radiol. 2006 Oct;36(10):1032-6. Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, Mongey AB, Strife CF, Graham TB, Passo MH. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus. 2006;15(4):198-206.
Mitsnefes MM, Subat-Dezulovic M, Khoury PR, Goebel J, Strife CF. Increasing incidence of post-kidney transplant anemia in children. Am J Transplant. 2005 Jul;5(7):1713-8.
Omoloja AA, Kumar K, Crawford AH, Strife CF. Epiphyseal stapling and recombinant human growth hormone for correction of genu valgum in children with chronic renal insufficiency. J Pediatr Orthop. 2003 Sep-Oct;23(5):639-42. Lande MB, Gullion C, Hoss RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S, Strife CF, Arbus G. Long versus standard initial steroid therapy for children with the nehprotic syndrome. A report from the Southwest Pediatric Nephrology Study. Pediatr Nephrol. 2003;18:342-6. Chand DH, Rhoades T, Poe SA, Kraus S, Strife CF. Incidence and severity of vesicoureteral reflux in children related to age, gender, race and diagnosis. J Urol. 2003;170:1548-1550. Chand DH, Poe SA, Strife CF. Venous pressure monitoring does not accurately predict access failure in children. Pediatr Nephrol. 2002;17:765-770. Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF. Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol. 2001 Apr;16(4):318-23. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000 Sep;14(10-11):898-902.
Grants
|
Rene D. Van De Voorde III, MD
Medical Director, Dialysis Unit
focuses on clinical research in the sequelae, treatment, and outcomes of chronic kidney disease, including end stage renal disease. He is currently involved in drug trials and research projects on the treatment of anemia (2 studies), bone and mineral disease (3 studies), poor growth, cardiovascular disease, and quality of life (1 study each).
513-636-4531
rene.vandevoorde@cchmc.org
Rene D. Van De Voorde III, MD
Medical Director, Dialysis Unit
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Dialysis; primarily infant dialysis; chronic kidney disease; acute kidney injury; hypertension
Biography
Education and Training
MD: Vanderbilt University.
Residency: Pediatrics, Cincinnati Children's Hospital.
Chief Resident: Pediatrics, Cincinnati Children's Hospital.
Fellowship: Pediatric Nephrology, Cincinnati Children's Hospital.
Certification: Pediatrics, 2003; Pediatric Nephrology, 2008.
Publications
View PubMed Publications
VanDeVoorde RG, Mitsnefes MM. Hypertension in chronic kidney disease in children. Advances in Chronic Kidney Disease. 2011. Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. Clin J Am Soc Nephrol. 2010 Sep;5(9):1552-7. Alon US, VandeVoorde RG. Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Pediatr Nephrol. 2010 Sep;25(9):1747-50. Bredrup C, Matejas V, Barrow M, Bláhová K, Bockenhauer D, Fowler DJ, Gregson RM, Maruniak-Chudek I, Medeira A, Mendonça EL, Kagan M, Koenig J, Krastel H, Kroes HY, Saggar A, Sawyer T, Schittkowski M, Swietliński J, Thompson D, VanDeVoorde RG, Wittebol-Post D, Woodruff G, Zurowska A, Hennekam RC, Zenker M, Russell-Eggitt I. Ophthalmological aspects of Pierson syndrome. Am J Ophthalmol. 2008 Oct;146(4):602-611. VanDe Voorde RG, Mitsnefes MM. Ambulatory blood pressure monitoring: a quest for truth. Pediatr Transplant. 2007 Feb;11(1):10-3. Wuhl E, Kogan J, Zurowska A, Matejas V, VanDeVoorde RG, Aigner T, Wendler O, Lesniewska I, Bouvier R, Reis A, Weis J, Cochat P, Zenker M. Neuro-developmental deficits in Pierson (microcoria-congenital nephrosis) Syndrome. American Journal of Medical Genetics (A). 2007;143(4):311-9. VanDeVoorde RG, Barletta G, Chand D, Dresner IG, Lane J, Leiser J, Lin JJ, Pan CG, Patel H, Valentini RP, Mitsnefes MM. Status of Blood Pressure Control in Children on Maintenance Hemodialysis: The Midwest Pediatric Nephrology Consortium (MWPNC) Study. Pediatric Nephrology. 2007;22(4):547-53. VanDeVoorde R, Witte D, Kogan J, Goebel J. Pierson Syndrome: A Novel Cause of Congenital Nephrotic Syndrome. Pediatrics. 2006;118(2):E1-5.
Grants
Prospective, Multicenter Study to Evaluate the Safety of Vitamin D Receptor Activators as Determined by Hypercalcemia in Pediatric Patients ages 0 to 16 with Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis within Current Clinical Practice. Site- Principal Investigator. Jun 2010 - present.
Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Dialysis dependent Chronic Kidney Disease. Site Co-investigator. AMAG Pharmaceutical. Apr 2011 - present. Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Non-dialysis dependent Chronic Kidney Disease. Site-Principal Investigator. AMAG Pharmaceuticals. Apr 2011 - present.
|
Clark D. West, MD
Emeritus Physician
has been a pioneer in fluid and electrolyte therapy for children as well as complement-mediated renal diseases. He is one of the true founding fathers of the field of pediatric nephrology. Dr. West's career includes the introduction of cyclophosphamide for nephrotic syndrome and the therapy for hypophosphatemic rickets. His research led to understanding the hypocomplementemic glomerulonephritides.
Clark D. West, MD
Emeritus Physician
Academic Information
Emeritus, UC Department of Pediatrics
Show All
Biography
Education and Training
MD: University of Michigan Medical School, 1943
Publications
View PubMed Publications
West CD, Bissler JJ. Nephritic factor and recurrence in the renal transplant of membranoproliferative glomerulonephritis type II. Pediatr Nephrol. 2008 Oct;23(10):1867-76
West CD. A hemolytic method for the measurement of nephritic factor. J Immunol Methods. 2008 Jun 1;335(1-2):1-7.
Grants
|
